Studies involving rituximab and/or CHOP resistant B-NHL cell lines reported the increased expression of anti-apoptotic BCL2 family members, including BCL2, BCL-XL or MCL1, while specific inhibitors targeting these proteins abrogated these effects [71,72]. This evidence concerns the gene BCL2 and non-Hodgkin lymphoma.